Plain language summary of the TOPAZ-1 study: durvalumaband chemotherapy for advanced biliary tract cancer' (vol 19, pg 2277, 2023)

被引：0
|
作者：
Oh, Do-You
He, Aiwu Ruth
Qin, Shukui
Chen, Li-Tzong
Okusaka, Takuji
Vogel, Arndt
Kim, Jin Won
Suksombooncharoen, Thatthan
Lee, Myung Ah
Kitano, Masayuki
Burris, Howard
Bouattour, Mohamed
Tanasanvimon, Suebpong
McNamara, Mairead G.
Zaucha, Renata
Avallone, Antonio
Tan, Benjamin
Cundom, Juan
Lee, Choong-Kun
Takahashi, Hidenori
Ikeda, Masafumi
Chen, Jen-Shi
Wang, Julie
Makowsky, Mallory
Rokutanda, Nana
Zotkiewicz, Magdalena
Kurland, John F.
Cohen, Gordon
Valle, Juan W.
机构：
来源：
FUTURE ONCOLOGY | 2024年 / 20卷 / 06期
关键词：
D O I：
10.2217/fon-2023-0468c1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：349 / 349
页数：1
相关论文
共 50 条
  • [1] Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
    Oh, Do-Youn
    He, Aiwu Ruth
    Qin, Shukui
    Chen, Li-Tzong
    Okusaka, Takuji
    Vogel, Arndt
    Kim, Jin Won
    Suksombooncharoen, Thatthan
    Lee, Myung Ah
    Kitano, Masayuki
    Burris, Howard
    Bouattour, Mohamed
    Tanasanvimon, Suebpong
    McNamara, Mairead G.
    Zaucha, Renata
    Avallone, Antonio
    Tan, Benjamin
    Cundom, Juan
    Lee, Choong-kun
    Takahashi, Hidenori
    Ikeda, Masafumi
    Chen, Jen-Shi
    Wang, Julie
    Makowsky, Mallory
    Rokutanda, Nana
    Zotkiewicz, Magdalena
    Kurland, John F.
    Cohen, Gordon
    Valle, Juan W.
    FUTURE ONCOLOGY, 2023, 19 (34) : 2277 - 2289
  • [2] Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1)
    Choe, Jung Wan
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2023, 82 (02): : 105 - 106
  • [3] Potentially prognostic factors of overall survival in advanced biliary tract cancer in the randomised phase III TOPAZ-1 study
    He, A. R.
    Bouattour, M.
    Gupta, V. G.
    Evesque, L.
    Zhen, D. B.
    Park, J. O.
    Sookprasert, A.
    Salvatierra, A.
    Vaccaro, G. M.
    Oh, S. C.
    Ostoich, S. A.
    Satoh, T.
    Zotkiewicz, M.
    Rokutanda, N.
    Kim, H.
    Oh, D-Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S220 - S220
  • [4] Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer
    Finkelmeier, Fabian
    Bouattour, Mohamed
    Valle, Juan
    Vogel, Arndt
    Kim, Jin Won
    Kitano, Masayuki
    Chen, Jen-Shi
    Burris, Howard
    Zaucha, Renata
    Qin, Shukui
    Evesque, Ludovic
    Zhen, David B.
    Gupta, Vineet Govinda
    Park, Joon Oh
    Zotkiewicz, Magdalena
    Rokutanda, Nana
    Cohen, Gordon
    Oh, Do-Youn
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 63 - 64
  • [5] Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial
    Zhao, Qiuling
    Xie, Ruixiang
    Zhong, Wanfu
    Liu, Wenbin
    Chen, Ting
    Qiu, Xiuliang
    Yang, Lin
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [6] Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer
    Finkelmeier, F.
    Bouattour, M.
    Valle, J. W.
    Vogel, A.
    Kim, J. W.
    Kitano, M.
    Chen, J. -S.
    Burris, H.
    Zaucha, R.
    Qin, S.
    Evesque, L.
    Zhen, D. B.
    Gupta, V. G.
    Park, J. O.
    Zotkiewicz, M.
    Rokutanda, N.
    Cohen, G.
    Oh, D. -Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 127 - 128
  • [7] Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial
    Qiuling Zhao
    Ruixiang Xie
    Wanfu Zhong
    Wenbin Liu
    Ting Chen
    Xiuliang Qiu
    Lin Yang
    Cost Effectiveness and Resource Allocation, 21
  • [8] Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer.
    Bouattour, Mohamed
    Valle, Juan W.
    Vogel, Arndt
    Kim, Jin Won
    Kitano, Masayuki
    Chen, Jen-Shi
    Burris, Howard A., III
    Zaucha, Renata
    Qin, Shukui
    Evesque, Ludovic
    Zhen, David Bing
    Gupta, Vineet Govinda
    Park, Joon Oh
    Zotkiewicz, Magdalena
    Rokutanda, Nana
    Cohen, Gordon
    Oh, Do-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 531 - 531
  • [9] Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
    Burris, Howard A., III
    Okusaka, Takuji
    Vogel, Arndt
    Lee, Myung Ah
    Takahashi, Hidenori
    Breder, Valeriy Vladimirovich
    Blanc, Jean-Frederic
    Li, Junhe
    Watras, Magdalena
    Xiong, Julia
    Abraham, Jayne
    Patel, Nikunj
    Wang, Julie
    Rokutanda, Nana
    Cohen, Gordon
    Oh, Do-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Immunotherapy for Patients with advanced biliary tract Cancer (BTC) 3-years Update of TOPAZ-1 Study showed Doubling of the Overall Survival Rate with Durvalumab and Chemotherapy Combination
    Sankawa, Yuri
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (06)
12345